FGI-104

FGI-104
Legal status
Legal status	US:Investigational New Drug;
Identifiers
	IUPAC name 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol;
PubChemCID	44158960;
ChemSpider	65322076;
CompTox Dashboard(EPA)	DTXSID201028023;
Chemical and physical data
Formula	C28H30ClN3O3
Molar mass	492.02g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO;
	InChI InChI=1S/C28H30ClN3O3/c1-4-32(5-2)16-20-12-22(31-25-10-11-30-26-14-21(29)8-9-23(25)26)15-24(28(20)34)18-6-7-19(17-33)27(13-18)35-3/h6-15,33-34H,4-5,16-17H2,1-3H3,(H,30,31); Key:OFXBJOIYAJBMNY-UHFFFAOYSA-N;

FGI-104is the name of an experimental broad-spectrumantiviral drug,with activity against a range of viruses includinghepatitis B,hepatitis C,HIV,Ebola virus,andVenezuelan equine encephalitis virus.^[1]

Mechanism[edit]

The drug acts by inhibiting the proteinTSG101,which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice fromEbola virus disease.^[2]^[3]

References[edit]

^Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009)."FGI-104: a broad-spectrum small molecule inhibitor of viral infection".American Journal of Translational Research.1(1): 87–98.doi:10.1016/j.antiviral.2009.02.082.PMC2776286.PMID 19966942.
^Janeba Z (November 2015)."Development of Small-Molecule Antivirals for Ebola".Medicinal Research Reviews.35(6): 1175–94.doi:10.1002/med.21355.PMC7168439.PMID 26172225.
^Saxena A, Ferri M (2015). "Clinical Management of Ebola Virus Disease: Current and Future Approaches". In Saxena A (ed.).Communicable Diseases of the Developing World.Topics in Medicinal Chemistry. Vol. 29. Cham: Springer. pp. 1–36.doi:10.1007/7355_2015_5003.ISBN 978-3-319-78252-2.

Thisantiinfective drugarticle is astub.You can help Wikipedia byexpanding it.

[KinchYunus2009-1] Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009)."FGI-104: a broad-spectrum small molecule inhibitor of viral infection".American Journal of Translational Research.1(1): 87–98.doi:10.1016/j.antiviral.2009.02.082.PMC2776286.PMID 19966942.

[Janeba2015-2] Janeba Z (November 2015)."Development of Small-Molecule Antivirals for Ebola".Medicinal Research Reviews.35(6): 1175–94.doi:10.1002/med.21355.PMC7168439.PMID 26172225.

[3] Saxena A, Ferri M (2015). "Clinical Management of Ebola Virus Disease: Current and Future Approaches". In Saxena A (ed.).Communicable Diseases of the Developing World.Topics in Medicinal Chemistry. Vol. 29. Cham: Springer. pp. 1–36.doi:10.1007/7355_2015_5003.ISBN 978-3-319-78252-2.

[1]

[2]

[3]

Mechanism[edit]

See also[edit]

References[edit]